Significance of monitoring imatinib plasma concentration in second-line treatment decisions for c-kit 11 gene-mutated gastrointestinal stromal tumors

Figure 2 Diagram of patient groups. Each group was further subdivided into Group A (dose-escalation group) and Group B (drug switch group) based on whether they received increased imatinib dosage (600 mg/day) or switched to another tyrosine kinase inhibitor. LP: Low plasma concentration group; HP: High plasma concentration group.